ABSTRACT We report here the serologic detection of a cell surface antigen common to cells transformed by the Abelson murine leukemia virus (A-MuLV) and to normal hematopoietic cells from certain strains of mice. Serum from C 7BL/6 mice hyperimmunized with syngeneic A-MuLV lymphoma cells was cytotoxic-for the immunizing cells; this reaction was used as the serologic test system'for recognition of A-MuLV antigens. Absorption analysis using 40 tumors and 21 cell lines revealed that two serologic specificities were detected by this test system: (i) 
expressed on all cells transformed by A-MuLV. The A-MuLVspecific antigen was also present on uninfected cells from BALB/c bone marrow, spteen, and fetal liver but not from adult liver, thyinus, lymph noes or peripheral blood. Abelson antigen was not expresse on bone marrow or spleen cells of 12 other mouse strains. In light of the original isolation of A-MuLV from a BALB/c mouse infected with Moloney virus, it is possible that Abelson anti'en is a serologic marker for a gene of BALB/c mice, normally encoding a cell surface molecule, that was incorporated into the Moloney virus genome during the generation of A-MuLV.
Serologic identification of cell surface antigens present on mouse leukemias has advanced considerably our knowledge of normal and malignant lymphoid differentiation (1) . Such studies have revealed the expression, at the cell surface, of gene products encoded by infecting murnne leukemia virus (MuLV) genomes [e.g., FMR, GCSA (2-4)], cell surface expression of gene products encoded by viral genes resident in the mouse genome [e.g., GIx (5) ], and cell surface expression of gene products specific for various steps in lymphoid differentiation [e.g., GIx, TL, Lyt-1, Lyt-2,3 (6) ]. Changes in the expression of several of these molecules have been closely correlated with the development of spontaneous or radiation-induced leukemia in mice (7, 8) . Recognition of cell surface antigens specifically associated with the directly transforming variants of MuLV, which presumably effect cell transformation by encoding a -gene product necessary for this phenotype, has thus far proved difficult (1, 9) . We report here the identification of such an antigen on lymphoma cells induced by the Abelson murine leukemia virus (A-MuLV).
A-MuLV was isolated from a rare nonthymic lymphoma of a BALB/c mouse that had been infected with Moloney MuLV (M-MuLV) and treated with prednisolone, a procedure that depletes the target cells for M-MuLV leukemogenesis (10) . A-MuLV shows a target cell specificity and a pathogenesis distinct from those of M-MuLV in that it rapidly and directly transforms lymphocytes of the bone marrow in vivo and in vitro (11) (12) (13) (14) . Like the other rapidly transforming variants of MuLV, A-MuLV occurs as a complex of two viruses. M-MuLV is-an infectious virus that provides functions necessary for the replication of the defective A-MuLV genome (15) . It is the deThe costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact.
fective virus genome that is responsible for the rapid lymphoma induction and the tissue specificity of A-MuLV (15) .
Studies on the pathogenesis of A-MuLV disease indicated that BALB/c mice are uniquely sensitive to lymphoma induction throughout their life, whereas most inbred strains of mice are susceptible as newborns but resistant as adults. Studies on adult mice revealed that the susceptible phenotype of BALB/c mice was dominant to the resistant phenotype of C57BL/6 (B6) mice (16) . These observations are consistent with the idea that genetic resistance to A-MuLV is effected by immunologic mechanisms and might be further interpreted to mean that the susceptibility of BALB/c mice to A-MuLV lymphoma induction is a consequence of their failure to efficiently recognize A-MuLV transformed cells as foreign, these mice being partially tolerant to A-MuLV cells. This last idea and the fact that A-MuLV originated from a BALB/c mouse (10) led us to test the hypothesis that A-MuLV induces a cell surface antigen crossreactive with one normally present in uninfected BALB/c mice but absent from other strains.
MATERIALS AND METHODS
Mice. Mice were bred in our colony at the McArdle-Laboratory or purchased from the Jackson Laboratory (Bar Harbor, ME).
Virus, Virus Assays, and Cell Lines. A-MuLV was prepared from lymphomas passaged in vivo in BALB/c mice (12) . AMuLV cloned in vitro was prepared from harvest fluids of ANN-1 cells productively infected with cloned M-MuLV (15 (1, 4, 5) . Antisera Preparation. B6 mice were selected for the production of antisera to A-MuLV lymphomas because adult B6 mice are resistant to A-MuLV lymphoma induction (16) and because transplanted B6 A-MuLV lymphomas frequently undergo regression after subcutaneous inoculation into adult mice. Ten-week-old female B6 mice were injected subcutaneously with 105-106 B6T1 cells. After these tumors had regressed (in about 2 weeks), the mice were given 3fold increasing numbers of tumor cells intraperitoneally every 2 weeks until a dose of 108 cells per mouse was reached, and this immunization dose was maintained. Mice were bled from the tail vein every 2 weeks after the sixth immunization, and sera from each group were pooled.
Cytotoxic and Absorption Assays. The cytotoxic assay was performed as described (4) . Selected rabbit serum was used as a source of complement (C) at a dilution of 1:5. Incubation of cells with complement alone resulted in 3-10% (mean, 7%) lysis in the 53 series of experiments in this study. Quantitative absorption assays were performed as described (5, 22) . For absorption experiments, antiserum was used at a concentration 4 times that which gave 50% B6T1 lysis in the direct test performed on that day. Unabsorbed antiserum at this dilution resulted in 70-90% (mean, 78%) B6T1 lysis in the 44 series of absorption experiments in this study. Cytotoxicity of absorbed serum has been corrected for daily variation in the sensitivity of B6T1 cells (70-90%) and daily variation in complement controls (3-10%) according to the formula: % lysis (absorbed serum) -complement control X 100 % lysis (unabsorbed serum) -complement control RESULTS Production of Anti-B6T1 Serum. B6 mice, hyperimmunized with cells from the syngeneic A-MuLV lymphoma B6T1, responded by making antibody cytotoxic for the immunizing cells ( Fig. 1) . Two separate groups of mice were used to prepare anti-B6T1 serum, and a third group was used to prepare antiserum to another independently derived B6 A-MuLV lymphoma B6T3. Serum pools from each of the three groups of mice (representing a total of 24 mice) had titers of 1/20 or greater when tested on B6T1 and contained antibodies de- (Table 2) . When anti-B6TI serum was absorbed with SC-I cells producing M-MuLV and then tested on B6T1 cells and on cells of the Rauscher MuLV B6 leukemia RBL-5, which does not carry the A-MuLV genome, cytotoxic activity remained for B6T1 cells but not for RBL-5 cells (Fig. 1, dashed lines) .
To confirm that only partial absorption of anti-B6TI cytotoxic activity for B6T1 cells could be attained with. cells expressing the FMR antigen(s), double absorptions of the anti-B6T1 serum were carried out. Anti-B6T1 serum was absorbed initially with SC-I cells producing M-MuLV, then reabsorbed with cells from each of the nine FMR tumors, and finally tested for cytotoxic activity on B6T1. The data in Table 1 and Fig. 3A clearly demonstrate that no further reduction of cytotoxic activity for B6T1 cells can be attained by repeated absorptions with FMR tumor cells. From these experiments we concluded that the anti-B6TI test system recognizes an FMR-type speci- Proc. Nati. Acad. Sci. USA 75 (1978) ficity and an additional specificity expressed on B6T1 cells.
Abelson antigen. Complete absorption of anti-B6Ti activity was attained only when A-MuLV tumor cells were tested (Table  1) . Quantitative absorption curves similar to thoe shown in Cells from 17 different lymphoid tumors did not absorb anti-B6Ti reactivity; these included spontaneous, radiationinduced, and carcinogen-induced tumors of AKR, A/J, BALB/c, and B6 mice. It is significant that BALB/c plasmacytomas were uniformly negative because, in conjunction with adjuvants, A-MuLV will induce this type of tumor (24) . To or MuLV-related antigens such as GIX or GCSA. The distinction between antigens detected by the anti-B6T1 test system and antigens of naturally occurring MuLV strains is further confirmed by the observation that spleen cells of AKR, C58, or NZB mice, which produce high titers of ecotropic or xenotropic MuLV (27, 28) (1978) quence of transformation by A-MuLV. The gene determining the structure of Abelson antigen in ANN-1, an A-MuLV nonproducer line derived from NIH 3T3, most likely was introduced as part of the virus genome, because bone marrow cells of mice from which the NIH 3T3 cell was established (the Swiss family of mice exemplified by SWR, NFS, and SJL) are Abelson antigen-negative and because fibroblastoid cells of Abelson antigen-positive strains do not express Abelson antigen (i.e., BALB/c 3T3 and BALB/c embryo fibroblasts). In addition an A-MuLV tumor of a random-bred rat and an A-MuLV nonproducer cell of rat origin express Abelson antigen, and rats would not be expected to carry repressed genes for mouse differentiation antigens. However, recognition of other antigenic systems, such as TL and GIX, that have features of differentiation antigens in some mouse strains and of leukemia-specific or MuLV-related antigens in others (1, 5) makes a final distinction between coding by viral genes or coding by normally silent host genes difficult to resolve. Molecular experiments will be needed to distinguish these possibilities.
The recent recognition of the recombinant nature of leukemogenic viruses of AKR mice (26, 30, 31) and of the defective spleen focus-forming virus of the Friend MuLV complex (32) raises the possibility that A-MuLV was similarly generated. Thus, Abelson antigen may be an antigenic determinant specified by a gene of BALB/c mice that was incorporated by recombination into the Moloney MuLV genome. Determining whether this BALB/c gene is a previously unrecognized endogenous MuLV gene or is a gene specifying a cell surface molecule involved in hematopoietic differentiation (two possibilities that are not mutually exclusive) will depend upon further definition of the Abelson antigen. The possibility that the viral gene product carrying the Abelson antigen evolved from a gene of M-MuLV through a process of mutation and selection must also be considered. The mode of replication of these viruses provides ample opportunity for mutation (33), and the immune system of the mouse in which such a virus evolves (in the case of A-MuLV, BALB/c mice) could well exert selective pressure for viral antigens that resemble normal cell surface constituents.
Abelson antigen may also provide an insight into the peculiar host range of A-MuLV among inbred mouse strains. Recent genetic results led to the recognition of two loci, Av-1 and Av-2, that act as dominant susceptibility factors to A-MuLV lymphoma induction in crosses of BALB/c with B6 mice (16) . The existence of these loci was deduced in part from the pattern of susceptibility to A-MuLV shown by CXB recombinant inbred lines, strains of mice that were generated by inbreeding pairs of (BALB/c X B6)F2 mice (23) . The pattern of expression of Abelson antigen shown by these seven recombinant inbred strains coincides with the inheritance of the Av-2 locus, positive antigen expression being correlated with partial sensitivity to A-MuLV (R. Risser, unpublished data). This finding might be interpreted to mean that expression of Abelson antigen, controlled by the Av-2 locus, acts to make mice partially tolerant to A-MuLV transformed cells that arise after virus infection. This hypothesis does not entirely account for A-MuLV susceptibility, however, because strains that do not express antigen (e.g., DBA/2, SWR, A/J) are somewhat susceptible to A-MuLV lymphoma induction. Furthermore, BALB/c mice are not tolerant to FMR antigen(s) (2, 3) 
